DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01509742

CompletedPhase 1

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

Effect of NNC 90-1170 on Hypoglycaemic Counterregulation During Stepwise Hypoglycaemic Clamp in Type 2 Diabetic Subjects. A Double-blind, Placebo-controlled, Randomised, 2-period Cross-over Trial

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

19

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Area under the Curve (AUC) glucagon

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01509742
Org study IDNN2211-1224

Timeline

Milestones

Study first posted2012-01-13estimated
Last update posted2024-02-01actual
Study start2001-04 (month precision)
Primary completion2001-11actual (month precision)
Study completion2001-11actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age30 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Eligibility criteria

age: minimum 30, maximum 75 years

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
5
Glycemic / diabetes
2
Safety / tolerability / PK
1

Glycemic / diabetes

2 endpoints
Secondary/protocol endpoint/low confidence

Insulin secretion

descriptive, improvement

Secondary/protocol endpoint/low confidence

Glucose

descriptive, improvement

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Adverse events

Treatment-emergent AEs (any)

descriptive, event

Other (unclassified)

5 endpoints
Primary/protocol endpoint/low confidence

Area under the Curve (AUC) glucagon

descriptive

Secondary/protocol endpoint/low confidence

Cortisol

descriptive

Secondary/protocol endpoint/low confidence

Growth hormone

descriptive

Secondary/protocol endpoint/low confidence

Adrenaline

descriptive

Secondary/protocol endpoint/low confidence

Noradrenaline

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.